

Help inform a differential diagnosis of Alzheimer's disease with Quest AD-Detect[®] p-tau217



Plasma p-tau217 delivers objective results that can help differentiate AD from other neurodegenerative diseases¹

The phosphorylated tau 217 (p-tau217) biomarker can help assess whether mild cognitive impairment (MCI) or dementia is caused by AD,¹⁻³ contributing to a more accurate diagnosis and personalized approaches to care inclusive of additional testing or interventions.

Less invasive, blood-based biomarker testing that may help with an earlier and precise AD diagnosis³



P-tau, inclusive of p-tau217, is a primary, **specific, blood-based biomarker for AD pathology.**³ Levels of p-tau217 in plasma correspond with amyloid status as assessed via CSF or PET imaging.¹⁻⁵




Elevated plasma p-tau217 helps to **predict progression of cognitive impairment and over time correlates with further cognitive decline** caused by AD⁶⁻⁷



Plasma p-tau217 can **differentiate AD from other neurodegenerative diseases**, such as frontotemporal dementia, progressive supranuclear palsy, and Parkinson's disease¹⁻³

Understanding p-tau217 plasma levels can help optimize care pathways



Visit [QuestForTheCure.com](https://www.questdiagnostics.com/questforthe cure) to learn more about our portfolio.

Transforming the cognitive health journey with actionable insights at every stage of patient care

We are proud to offer one of the most comprehensive cognitive health testing portfolios in the industry. Our innovative blood-based diagnostic solutions provide multiple tests for AD biomarkers, empowering you with the diagnostic insights you need to assess the potential risk for AD or dementia and improve the care pathway, inclusive of disease-associated risk, diagnosis, staging, monitoring, and treatment-associated risk.

Test code	Test name	Turnaround time	Test use
13825	Quest AD-Detect® Phosphorylated tau217 (p-tau217), Plasma	1-3 days	Determine levels of p-tau217 proteins, a dynamic and specific biomarker to aid in differentiating AD from other neurodegenerative diseases ³
11786	Quest AD-Detect® Beta-Amyloid 42/40 Ratio, Plasma	3-6 days	Detect beta-amyloid (Aβ) levels, one of the earliest biomarkers associated with AD risk ⁸ ; levels can be monitored over time
13690	Quest AD-Detect®, Phosphorylated tau181 (p-tau181), Plasma	1-3 days	Uncover the presence of p-tau181 proteins, one of the key biomarkers involved in the diagnosis and staging of AD ⁹ ; levels can be monitored over time
12563	Quest AD-Detect® Apolipoprotein E (ApoE), Plasma	3-10 days	Assess ApoE isoforms to help determine hereditary AD risk, ⁹ as well as risk for amyloid-related imaging abnormalities (ARIA)



Minimally invasive, blood-based biomarker testing can provide a comprehensive assessment of cognitive impairment and connect patients to a timely diagnosis and appropriate care at the earliest stages.

Visit QuestForTheCure.com to learn how we are advancing the science behind AD diagnostics.

References

1. Thijssen EH, Joie RL, Strom A, et al. Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. *Lancet Neurol.* 2021;20(9):739-752. doi:10.1016/s1474-4422(21)00214-3
2. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. *JAMA.* 2020;324(8):772-781. doi:10.1001/jama.2020.12134
3. Ashton NJ, Brum WS, Molfetta GD, et al. Diagnostic accuracy of a plasma phosphorylated tau 217 immunoassay for Alzheimer disease pathology. *JAMA Neurol.* 2024;81(3):255-263. doi:10.1001/jamaneurol.2023.5319
4. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in the community. *Nat Med.* 2022;28(7):1398-1405. doi:10.1038/s41591-022-01822-2
5. Therriault J, Ashton NJ, Pola I, et al. Comparison of two plasma p-tau217 assays to detect and monitor Alzheimer's pathology. *eBioMedicine.* 2024;102:105046. doi:10.1016/j.ebiom.2024.105046
6. Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease. *Brain.* 2020;143(11):3234-3241. doi:10.1093/brain/awaa286
7. Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures. *Nat Med.* 2021;27(6):1034-1042. doi:10.1038/s41591-021-01348-z
8. Nakamura A, Kaneko N, Villemagne V, et al. High performance plasma amyloid-B biomarkers for Alzheimer's disease. *Nature.* 2018;554(7691):249-254. doi:10.1038/nature25456
9. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer's disease biomarkers in a multi-ethnic, community study. *Alzheimers Dement.* 2021;17(8):1353-1364. doi:10.1002/alz.12301

Test codes may vary by location. Please contact your local laboratory for more information.

Image content features models and is intended for illustrative purposes only.

QuestDiagnostics.com

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2024 Quest Diagnostics Incorporated. All rights reserved. SB12921 4/2024